Legend Biotech reports Q3 2026 results, CARVYKTI sales up 36%, names new CEO
Five-year CARTITUDE-2 data and an FDA IND clearance for a new in vivo CAR-T candidate accompanied a leadership change and swing to profitability.
SEC filing
5 stories
Five-year CARTITUDE-2 data and an FDA IND clearance for a new in vivo CAR-T candidate accompanied a leadership change and swing to profitability.
SEC filing
The clearance paves the way for a planned U.S. Phase 1/2 study of the CD19/CD20 dual-targeting in vivo CAR-T therapy in relapsed or refractory B-cell malignancies.
SEC filing
At its September 24, 2026 annual meeting, Legend Biotech investors re-elected four directors and approved adding 19.1 million shares to its restricted share plan.
SEC filing
Zhang, formerly Novartis International's Chief Commercial Officer, succeeds interim CEO Alan Bash, who returns to lead the CARVYKTI business.
SEC filing